Archived series ("Inactive feed" status)
When? This feed was archived on March 16, 2022 21:28 (). Last successful fetch was on August 10, 2021 06:08 ()
Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 299555721 series 2906202
Martin Bryden and Dr. Nial Wheate join me from Canngea. We had a discussion about their business and what they are currently working on in the cannabis industry. We spoke on topics like the current state of the medical, nutraceutical, and recreational industries. Dr Nial Wheate broke down clinical trials and the bioavailability of cannabis.
To let you know Canngea is an Australian company that operates as a B2B Contract Manufacturing Organisation. They focus on Eu-GMP standards (Good Management Practices) and SOP’s (Standard Operating Procedures). Canngea can deliver consistent high-quality products at competitive rates.
They were established in Australia in September 2017. Canngea offers services to other companies in the medicinal cannabis industry to supply white label and private label solutions to produce products for wholesale in the domestic and international markets.